3篇
您的检索式：作者名="YE ChengYin"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A new approach to dissecting complex traits by combining quantitative trait transcript (QTT) mapping and diallel cross analysis显示文摘A promising way to uncover the genetic architectures underlying complex traits may lie in the ability to recognize the genetic variants and expression transcripts that are responsible for the traits' inheritance.However,statistical methods capable of investigating the association between the inheritance of a quantitative trait and expression transcripts are still limited.In this study,we described a two-step approach that we developed to evaluate the contribution of expression transcripts to the inheritance of a complex trait.First,a mixed linear model approach was applied to detect significant trait-associated differentially expressed transcripts.Then,conditional analysis were used to predict the contribution of the differentially expressed genes to a target trait.Diallel cross data of cotton was used to test the application of the approach.We proposed that the detected differentially expressed transcripts with a strong impact on the target trait could be used as intermediates for screening lines to improve the traits in plant and animal breeding programs.It can benefit the discovery of the genetic mechanisms underlying complex traits. | YANG DaiGang YE ChengYin MA XiongFeng ZHU ZhiHong ZHOU XiaoJian WANG HaiFeng MENG QingQin PEI XiaoYu YU ShuXun ZHU Jun | 2012 | Chinese Science Bulletin2012，57，21： | 3 |
| 2 | Insight into the formation of hollow silver nanoparticles using a facile hydrothermal strategy显示文摘 | Chengyin Li Hui Liu Penglei Cui Feng Ye Jun Yang | 2016 | Particuology2016，14，1： | 1 |
| 3 | Safety and immunogenicity of a modified COVID-19 mRNA vaccine,SYS6006,as a fourth-dose booster following three doses of inactivated vaccines in healthy adults:an open-labeled Phase 1 trial显示文摘The continuous emergence of the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants led to a rapid decline in protection efficacy and neutralizing titers even after three doses of COVID-19 vaccines.Here,we report an open-labeled Phase I clinical trial of a modified mRNA vaccine(SYS6006)as a fourth-dose booster in healthy adults.Eighteen eligible participants,who had completed three doses of inactivated COVID-19 vaccines,received a fourth boosting dose of SYS6006-20μg.Eighteen convalescent COVID-19 patients were enrolled for the collection of serum samples as a comparator of immunogenicity.The primary endpoint of this trial was titers of anti-receptor binding domain of spike glycoprotein(RBD)antibodies of the Omicron strain(BA.2 and BA.4/5)in serum;titers of neutralizing antibodies against pseudovirus of the Omicron strain(BA.2 and BA.4/5).The secondary endpoint was the incidence of adverse events within 30 days after the boosting.The exploratory endpoint was the cellular immune responses(interferon gamma,IFN-γ).This trial was registered with the Chinese Clinical Trial Registry website.No serious adverse events were reported within 30 days after vaccination.No Grade 3 fever or serious adverse event was reported in the SYS6006 group.Notably,SYS6006 elicited higher titers and longer increases in anti-RBD antibodies and neutralizing antibodies(>90 days)compared with the convalescent group(P<0.0001)against Omicron strain(BA.2 and BA.4/5).Besides,higher positive spots of T-cell-secreting IFN-γwere observed in the SYS6006 group than those in the convalescent group(P<0.05).These data demonstrated that SYS6006 was well tolerated and highly immunogenic,generating a stronger and more durable immune response against different variants of SARS-CoV-2. | Yuzhou Gui Ye Cao Jiajin He Chunyang Zhao Wei Zheng Ling Qian Jie Cheng Chengyin Yu Chen Yu Kun Lou Gangyi Liu Jingying Jia | 2023 | Life Metabolism2023，2，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员